NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/15/2025
Back to search
Official data from USPTO
GENOMIGON
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
04/03/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
02/06/2023
Registration date
02/25/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/25/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
01
Owner location
DE
Examiner
OH, HYUN-JUNG
Law office
O20
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "GENOMIGON" in blue. On the left side of the wording are twelve orange dots lined up to form a stylized orange helix. White represents background and/or transparent areas and is not claimed as a feature of the mark.
Holders and representatives
Holders
D. H. (pessoa física)
Representatives
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for the treatment of malignant tumor diseases and malignant and benign blood diseasesinfectious diseases; diagnostic preparations and materials for medical purposes; diagnostic substances for medical use; diagnostic testing materials for medical usemedical diagnostic test media in the form ofstripsthreadsliquidsgelsserumsfor measuringbiomarkers in malignant diseases and hereditary diseases on a genetic basis or protein basisgene variants in hereditary diseases and malignant diseases; medical diagnostic test strips for blood analysisurine analysissaliva analysis; biotechnological preparations for medical use in the nature of pharmaceutical preparations for the treatment of cancermalignant and non-malignant blood diseases and hereditary diseases; medicinecytostatics for medical purposesantibodies for medical purposesantibody-drug conjugatestherapeutically modified lymphocytesmixed hormone preparationspreparations for the targeted treatment of malignant and non-malignant diseases in the nature of targeted delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals that inhibitactivate or modulate regulatory cascades in malignant and non-malignant diseases or the microenvironment such as tyrosine kinase inhibitorsantibodiesantibody drug conjugatesimmune checkpoint inhibitorsT cell engagersmodified effector cell preparations such as CAR-T cellsbispecific or multispecific antibodiesantibody-nuclide conjugates; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for the treatment ofmalignant blood diseasesbenign blood diseasesmalignant solid tumorsbenign solid tumorscancer and hereditary diseases; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for healing or alleviating ailments and reducing symptoms of blood diseases; biological preparations for medical purposesbiological preparations for the treatment ofmalignant blood diseasesbenign blood diseasesmalignant solid tumorsbenign solid tumors; all the aforesaid goods relating to the fields of oncologychemotherapymolecular geneticsmolecular medicine
Class 10
Genetic testing apparatus for medical purposes; diagnostic equipment and instruments for medical purposes for the analysis of body fluidsbenign and malignant tissue and bloodprotein structures of tumorsgenetic code of tissue and blood cellsanalysis of blood cellsblood plasma and blood serum; medical apparatus for carrying-out diagnostic tests for medical purposes for cancer cellsleukemia cellsbenign and malignant cells of humans and animalsgenetic material; medical testing instruments for medical diagnostic purposes for blood sugar levelscancer cellsgenetic material; electromedical diagnostic instrumentselectromedical rehabilitative and pain management products for clinical and home useelectrical nerve and muscle stimulatorsultrasonic stimulatorsmagnet therapy stimulators and laser therapy stimulators; radiation instrumentsfor medical purposesradiation therapy devices; medical radiation apparatus for medical purposes; medical apparatus for the treatment of cancer; apparatus for DNA and RNA testing for medical purposes; all the aforesaid goods relating to the fields of oncologychemotherapymolecular geneticsmolecular medicine
Class 42
Scientific analysis in the field of pharmaceuticalsmedical devices; scientific research in the field of geneticshematologyoncology; genetic scientific research; pharmaceutical research services; clinical research in the field of radiologyradiotherapysurgical medicineoncological system therapy of malignant and benign diseasesinfectious diseases; research relating to biotechnology; medical research; computer aided diagnostic testing servicesdiagnostic services for others for scientific research purposes; design and development of medical diagnostic apparatus; design and development of medical technology; development of pharmaceutical preparations and medicines; provision of information and data relating to medical and veterinary research and development; consultancy relating to research and development in the field of therapeutics; providing scientific research information in the field of medical disorders and their treatment; laboratory testing and analysis for medical research purposes in the field of bacteriologychemistrylife sciencemolecular geneticsprotein diagnosticsoncologyhematologyradiologyradiotherapy; biomedical assay services and development for the analysis of body fluidstissue samples and fluids and blood and blood products for benign and malignant diseases in the field of diagnostic preparationsimplements and medication; all the aforesaid services relating to the fields of oncologychemotherapymolecular geneticsmolecular medicine
Class 44
Medical services; medical analysis services relating to disease managementdisease diagnosis servicesdisease prognosis; medical laboratory services for the analysis of samples taken from patients; health screening services in the field of malignant tumor diseasesbenign tumor diseasesmalignant blood diseasesbenign blood diseaseshereditary diseasescoagulation disorders; providing medical information in the healthcare sector; medical consultations; arranging of medical treatment in the field of oncologyhematologygeneticsgene therapiestargeted therapycell therapies; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; all the aforesaid services relating to the fields of oncologychemotherapymolecular geneticsmolecular medicine
Publications
History of USPTO decisions and trademark events.
36 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/27/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/07/2025
FIMP
FINAL DISPOSITION PROCESSED
09/07/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/25/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/25/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/25/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/07/2025
PUBO
PUBLISHED FOR OPPOSITION
01/07/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/01/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/10/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
12/10/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/10/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
12/10/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/05/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/23/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/06/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/06/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/11/2024
GNFR
FINAL REFUSAL E-MAILED
06/11/2024
CNFR
FINAL REFUSAL WRITTEN
06/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/07/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/07/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/07/2024
RFNP
REFUSAL PROCESSED BY IB
12/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/15/2023
RFRR
REFUSAL PROCESSED BY MPU
11/15/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/14/2023
CNRT
NON-FINAL ACTION WRITTEN
11/13/2023
DOCK
ASSIGNED TO EXAMINER
11/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
06/16/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/12/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/08/2023
Continuous trademark protection
Get notified about every new filing that threatens GENOMIGON or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.